{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:28:16Z","timestamp":1790238496933,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173131"],"award-info":[{"award-number":["82173131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["CYJ20240813095300002"],"award-info":[{"award-number":["CYJ20240813095300002"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010124"],"award-info":[{"award-number":["2023A1515010124"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012783"],"award-info":[{"award-number":["2024A1515012783"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Enzalutamide, as a second-generation anti-androgen agent, has been used to treat castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC). However, enzalutamide resistance inevitably developed for most treated CRPC\/mCSPC, and limited effective therapies are currently available for these enzalutamide-resistant prostate cancers. In this study, we utilize our established enzalutamide-resistant prostate cancer cell lines to reveal a vulnerability of these cancer cells to GPX4-targeted ferroptosis. Interestingly, the established enzalutamide-resistant prostate cancer cells are mixed populations that predominantly exhibit stem cell-like (SCL) and neuroendocrine-like (NEL) phenotypes and may reflect cellular heterogeneity during the development of enzalutamide resistance in prostate cancer. We further demonstrated that ACSL4, a long-chain fatty acid-CoA ligase, was upregulated by the JAK\/STAT pathway in enzalutamide-resistant SCL\/NEL cells, thereby facilitating tumor proliferation and metastasis while increasing sensitivity to ferroptosis. To antagonize the ACSL4-conferred ferroptosis risk, SCL\/NEL cells upregulated GPX4 through AP-1 transcription complex to suppress ferroptosis and thus promoted the malignant progression of SCL\/NEL cells. Notably, we characterized Auranofin, an anti-rheumatoid arthritis drug, as a ferroptosis inducer for these SCL\/NEL cells in vitro and in vivo by targeting AP-1 and decreasing GPX4 expression, suggesting a new application for Auranofin in treating enzalutamide-resistant stem cell-like AP-1\n                    <jats:sup>High<\/jats:sup>\n                    CRPC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08906-8","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:14:50Z","timestamp":1780049690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism"],"prefix":"10.1038","volume":"17","author":[{"given":"Yi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-3412","authenticated-orcid":false,"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangsang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-6922","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-5235","authenticated-orcid":false,"given":"Chris Soon Heng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0881-0936","authenticated-orcid":false,"given":"Ju","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-3873","authenticated-orcid":false,"given":"Bin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-1603","authenticated-orcid":false,"given":"Hailiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"8906_CR1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589\u2013604.","journal-title":"Ann Oncol"},{"key":"8906_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.","journal-title":"N Engl J Med"},{"key":"8906_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"8906_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78\u201383.","journal-title":"Science."},{"key":"8906_CR5","doi-asserted-by":"publisher","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","volume":"376","author":"F Tang","year":"2022","unstructured":"Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376:eabe1505.","journal-title":"Science."},{"key":"8906_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"8906_CR7","doi-asserted-by":"publisher","first-page":"12742","DOI":"10.3390\/ijms222312742","volume":"22","author":"M Kanayama","year":"2021","unstructured":"Kanayama M, Luo J. Delineating the molecular events underlying development of prostate cancer variants with neuroendocrine\/small cell carcinoma characteristics. Int J Mol Sci. 2021;22:12742.","journal-title":"Int J Mol Sci"},{"key":"8906_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9:2404.","journal-title":"Nat Commun"},{"key":"8906_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29963-5","volume":"13","author":"S Nouruzi","year":"2022","unstructured":"Nouruzi S, Ganguli D, Tabrizian N, Kobelev M, Sivak O, Namekawa T. ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nat Commun. 2022;13:2282.","journal-title":"Nat Commun"},{"key":"8906_CR10","first-page":"1584","volume":"196","author":"A Atala","year":"2016","unstructured":"Atala A. Re: N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. J Urol. 2016;196:1584\u20135.","journal-title":"J Urol"},{"key":"8906_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 2017;7:54\u201371.","journal-title":"Cancer Discov"},{"key":"8906_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08133-6","volume":"10","author":"H Guo","year":"2019","unstructured":"Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10:278.","journal-title":"Nat Commun"},{"key":"8906_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11:213\u20139.","journal-title":"Nat Rev Urol"},{"key":"8906_CR14","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, Wen SJ, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621\u201330.","journal-title":"Clin Cancer Res"},{"key":"8906_CR15","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.3390\/genes12121900","volume":"12","author":"LP Chaves","year":"2021","unstructured":"Chaves LP, Melo CM, Saggioro FP, Reis RBD, Squire JA. Epithelial-mesenchymal transition signaling and prostate cancer stem cells: emerging biomarkers and opportunities for precision therapeutics. Genes. 2021;12:1900.","journal-title":"Genes."},{"key":"8906_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.chembiol.2008.02.010","volume":"15","author":"WS Yang","year":"2008","unstructured":"Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15:234\u201345.","journal-title":"Chem Biol"},{"key":"8906_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell."},{"key":"8906_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S. Ingo IdI, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u20138.","journal-title":"Nat Chem Biol"},{"key":"8906_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan BY. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"8906_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","volume":"133","author":"TM Seibt","year":"2019","unstructured":"Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2019;133:144\u201352.","journal-title":"Free Radic Biol Med"},{"key":"8906_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li ZP, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688.","journal-title":"Nature."},{"key":"8906_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41589-020-0613-y","volume":"16","author":"M Soula","year":"2020","unstructured":"Soula M, Weber RA, Zilka O, Alwaseem H, La K, Yen F, et al. Metabolic determinants of cancer cell sensitivity to canonical ferroptosis inducers. Nat Chem Biol. 2020;16:1351.","journal-title":"Nat Chem Biol"},{"key":"8906_CR23","doi-asserted-by":"publisher","first-page":"e2006203","DOI":"10.1371\/journal.pbio.2006203","volume":"16","author":"H Feng","year":"2018","unstructured":"Feng H, Stockwell BR. Unsolved mysteries: how does lipid peroxidation cause ferroptosis? PLoS Biol. 2018;16:e2006203.","journal-title":"PLoS Biol"},{"key":"8906_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nchembio.2079","volume":"12","author":"K Shimada","year":"2016","unstructured":"Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016;12:497\u2013503.","journal-title":"Nat Chem Biol"},{"key":"8906_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41589-020-0501-5","volume":"16","author":"JK Eaton","year":"2020","unstructured":"Eaton JK, Furst L, Ruberto RA, Moosmayer D, Hilpmann A, Ryan MJ, et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat Chem Biol. 2020;16:497\u2013506.","journal-title":"Nat Chem Biol"},{"key":"8906_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41401-022-00981-9","volume":"44","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li XM, Shi XH, Ye K, Fu XL, Wang X, et al. Sorafenib triggers ferroptosis via inhibition of HBXIP\/SCD axis in hepatocellular carcinoma. Acta Pharm Sin. 2023;44:622\u201334.","journal-title":"Acta Pharm Sin"},{"key":"8906_CR27","doi-asserted-by":"publisher","first-page":"e35882","DOI":"10.1016\/j.heliyon.2024.e35882","volume":"10","author":"M Jiang","year":"2024","unstructured":"Jiang M, Wu S, Xie K, Zhou G, Zhou W, Bao P. The significance of ferroptosis in renal diseases and its therapeutic potential. Heliyon. 2024;10:e35882.","journal-title":"Heliyon."},{"key":"8906_CR28","first-page":"323","volume":"19","author":"Y Li","year":"2020","unstructured":"Li Y, Yan HY, Xu XM, Liu HB, Wu C, Zhao L. Erastin\/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2\/xCT pathway. Oncol Lett. 2020;19:323\u201333.","journal-title":"Oncol Lett"},{"key":"8906_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03998-w","volume":"12","author":"JS Zheng","year":"2021","unstructured":"Zheng JS, Sato M, Mishima E, Sato H, Proneth B, Conrad M. Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines. Cell Death Dis. 2021;12:698.","journal-title":"Cell Death Dis"},{"key":"8906_CR30","doi-asserted-by":"publisher","first-page":"e2012748118","DOI":"10.1073\/pnas.2012748118","volume":"118","author":"LF Xu","year":"2021","unstructured":"Xu LF, Yin Y, Li YJ, Chen XF, Chang Y, Zhang H, et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci USA. 2021;118:e2012748118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8906_CR31","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.3390\/cancers13163957","volume":"13","author":"H Xu","year":"2021","unstructured":"Xu H, Li SS, Sun Y, Xu LF, Hong X, Wang Z, et al. ELOVL5-mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer. Cancers. 2021;13:3957.","journal-title":"Cancers."},{"key":"8906_CR32","doi-asserted-by":"publisher","first-page":"e166647","DOI":"10.1172\/JCI166647","volume":"133","author":"ME Wang","year":"2023","unstructured":"Wang ME, Chen JQ, Lu Y, Bawcom AR, Wu JJ, Ou JH, et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis. J Clin Invest. 2023;133:e166647.","journal-title":"J Clin Invest"},{"key":"8906_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32701-6","volume":"13","author":"TC Westbrook","year":"2022","unstructured":"Westbrook TC, Guan XN, Rodansky E, Flores D, Liu CJ, Udager AM, et al. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022;13:5345.","journal-title":"Nat Commun"},{"key":"8906_CR34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1021\/acschembio.5b00245","volume":"10","author":"SJ Dixon","year":"2015","unstructured":"Dixon SJ, Winter GE, Musavi LS, Lee ED, Snijder B, Rebsamen M, et al. Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol. 2015;10:1604\u20139.","journal-title":"ACS Chem Biol"},{"key":"8906_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"8906_CR36","doi-asserted-by":"publisher","first-page":"174397","DOI":"10.1016\/j.ejphar.2021.174397","volume":"909","author":"J Quan","year":"2021","unstructured":"Quan J, Bode AM, Luo X. ACSL family: the regulatory mechanisms and therapeutic implications in cancer. Eur J Pharm. 2021;909:174397.","journal-title":"Eur J Pharm"},{"key":"8906_CR37","doi-asserted-by":"publisher","first-page":"184084","DOI":"10.1016\/j.bbamem.2022.184084","volume":"1865","author":"R Baccouch","year":"2023","unstructured":"Baccouch R, Shi Y, Vernay E, Mathelie-Guinlet M, Taib-Maamar N, Villette S, et al. The impact of lipid polyunsaturation on the physical and mechanical properties of lipid membranes. Biochim Biophys Acta Biomembr. 2023;1865:184084.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"8906_CR38","first-page":"1271","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, et al. Author Correction: Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat. Cancer. 2022;3:1271.","journal-title":"Cancer."},{"key":"8906_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1126\/science.aan0346","volume":"359","author":"CSH Tan","year":"2018","unstructured":"Tan CSH, Go KD, Bisteau X, Dai L, Yong CH, Prabhu N, et al. Thermal proximity coaggregation for system-wide profiling of protein complex dynamics in cells. Science. 2018;359:1170\u20137.","journal-title":"Science."},{"key":"8906_CR40","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.chembiol.2023.08.002","volume":"30","author":"H Ji","year":"2023","unstructured":"Ji H, Lu X, Zhao S, Wang Q, Liao B, Bauer LG, et al. Target deconvolution with matrix-augmented pooling strategy reveals cell-specific drug-protein interactions. Cell Chem Biol. 2023;30:1478\u201387.e7.","journal-title":"Cell Chem Biol"},{"key":"8906_CR41","doi-asserted-by":"publisher","first-page":"883297","DOI":"10.3389\/fmolb.2022.883297","volume":"9","author":"M Jovanovic","year":"2022","unstructured":"Jovanovic M, Podolski-Renic A, Krasavin M, Pesic M. The role of the thioredoxin detoxification system in cancer progression and resistance. Front Mol Biosci. 2022;9:883297.","journal-title":"Front Mol Biosci"},{"key":"8906_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1382","volume":"2","author":"K Fritz-Wolf","year":"2011","unstructured":"Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, Becker K. Crystal structure of the human thioredoxin reductase-thioredoxin complex. Nat Commun. 2011;2:383.","journal-title":"Nat Commun"},{"key":"8906_CR43","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.bcp.2008.08.021","volume":"76","author":"AG Cox","year":"2008","unstructured":"Cox AG, Brown KK, Arner ESJ, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax\/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharm. 2008;76:1097\u2013109.","journal-title":"Biochem Pharm"},{"key":"8906_CR44","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1158\/0008-5472.CAN-24-3478","volume":"85","author":"SL DeAngelo","year":"2025","unstructured":"DeAngelo SL, Zhao L, Dziechciarz S, Shin M, Solanki S, Balia A, et al. Recharacterization of the tumor suppressive mechanism of RSL3 identifies the selenoproteome as a druggable pathway in colorectal cancer. Cancer Res. 2025;85:2788\u2013804.","journal-title":"Cancer Res"},{"key":"8906_CR45","doi-asserted-by":"publisher","first-page":"311.","DOI":"10.1038\/s41698-025-01090-6","volume":"9","author":"A Manas","year":"2025","unstructured":"Manas A, Seger A, Adamska A, Smyrilli K, Siaw JT, Radke K. et al. Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma. Npj Precis Oncol. 2025;9:311.","journal-title":"Npj Precis Oncol."},{"key":"8906_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-023-02677-2","volume":"42","author":"A Saha","year":"2023","unstructured":"Saha A, Zhao SY, Kindall A, Wilder C, Friedman CA, Clark R, et al. Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition. J Exp Clin Canc Res. 2023;42:119.","journal-title":"J Exp Clin Canc Res"},{"key":"8906_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2019.01.004","volume":"846","author":"NN Liu","year":"2019","unstructured":"Liu NN, Guo ZQ, Xia XH, Liao YN, Zhang FC, Huang CY, et al. Auranofin lethality to prostate cancer includes inhibition of proteasomal deubiquitinases and disrupted androgen receptor signaling. Eur J Pharmacol. 2019;846:1\u201311.","journal-title":"Eur J Pharmacol"},{"key":"8906_CR48","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1126\/science.6429854","volume":"225","author":"K Tepperman","year":"1984","unstructured":"Tepperman K, Finer R, Donovan S, Elder RC, Doi J, Ratliff D, et al. Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science. 1984;225:430\u20132.","journal-title":"Science"},{"key":"8906_CR49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"8906_CR50","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu HF, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer a living systematic review and network meta-analysis. JAMA Oncol. 2023;9:635\u201345.","journal-title":"JAMA Oncol"},{"key":"8906_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479\u201399.","journal-title":"Annu Rev Med"},{"key":"8906_CR52","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"MP Cai","year":"2023","unstructured":"Cai MP, Song XL, Li XA, Chen MK, Guo JD, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Update. 2023;68:100962.","journal-title":"Drug Resist Update"},{"key":"8906_CR53","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ccell.2023.06.010","volume":"41","author":"X Li","year":"2023","unstructured":"Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson NA, et al. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer Cell. 2023;41:1427\u201349.e12.","journal-title":"Cancer Cell"},{"key":"8906_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18:79\u201392.","journal-title":"Nat Rev Urol"},{"key":"8906_CR55","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro SC, Leshchiner I, Haase K, Tarabichi M, Wintersinger J, Deshwar AG, et al. Characterizing genetic intra-tumor heterogeneity across 2658 human cancer genomes. Cell. 2021;184:2239\u201354.e39.","journal-title":"Cell."},{"key":"8906_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12:1426.","journal-title":"Nat Commun"},{"key":"8906_CR57","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s42003-020-01476-1","volume":"3","author":"B Dong","year":"2020","unstructured":"Dong B, Miao J, Wang Y, Luo W, Ji Z, Lai H, et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun Biol. 2020;3:778.","journal-title":"Commun Biol"},{"key":"8906_CR58","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.ccell.2023.10.009","volume":"41","author":"CC Chen","year":"2023","unstructured":"Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, et al. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023;41:2066\u201382.e9.","journal-title":"Cancer Cell"},{"key":"8906_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81:446\u201355.","journal-title":"Eur Urol"},{"key":"8906_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7\u201318.","journal-title":"Eur J Cancer"},{"key":"8906_CR61","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31:617\u201339.","journal-title":"Cell Stem Cell"},{"key":"8906_CR62","doi-asserted-by":"publisher","first-page":"e2420313122","DOI":"10.1073\/pnas.2420313122","volume":"122","author":"J Lee","year":"2025","unstructured":"Lee J, Park J, Hur Y, Um D, Choi HS, Park J, et al. ETV5 reduces androgen receptor expression and induces neural stem-like properties during neuroendocrine prostate cancer development. Proc Natl Acad Sci USA. 2025;122:e2420313122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8906_CR63","doi-asserted-by":"publisher","first-page":"101949","DOI":"10.1016\/j.redox.2021.101949","volume":"42","author":"L Freire Boullosa","year":"2021","unstructured":"Freire Boullosa L, Van Loenhout J, Flieswasser T, De Waele J, Hermans C, Lambrechts H, et al. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Redox Biol. 2021;42:101949.","journal-title":"Redox Biol"},{"key":"8906_CR64","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-020-00253-0","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Wang H, Yang X, Wu Q, An P, Jin X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms. Signal Transduct Target Ther. 2020;5:138.","journal-title":"Signal Transduct Target Ther"},{"key":"8906_CR65","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.7150\/thno.52077","volume":"11","author":"Y Xia","year":"2021","unstructured":"Xia Y, Chen J, Yu Y, Wu F, Shen X, Qiu C, et al. Compensatory combination of mTOR and TrxR inhibitors to cause oxidative stress and regression of tumors. Theranostics. 2021;11:4335\u201350.","journal-title":"Theranostics."},{"key":"8906_CR66","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.freeradbiomed.2012.03.013","volume":"52","author":"CR Myers","year":"2012","unstructured":"Myers CR. The effects of chromium(VI) on the thioredoxin system: implications for redox regulation. Free Radic Biol Med. 2012;52:2091\u2013107.","journal-title":"Free Radic Biol Med"},{"key":"8906_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cbi.2017.07.020","volume":"275","author":"XQ Zheng","year":"2017","unstructured":"Zheng XQ, Xu W, Sun RX, Yin HW, Dong CR, Zeng HH. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells. Chem Biol Interact. 2017;275:74\u201385.","journal-title":"Chem Biol Interact"},{"key":"8906_CR68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/antiox12010100","volume":"12","author":"XJ Ma","year":"2023","unstructured":"Ma XJ, Dong XW, Xu Y, Ma N, Wei M, Xie XC, et al. Identification of AP-1 as a critical regulator of glutathione peroxidase 4 (GPX4) transcriptional suppression and acinar cell ferroptosis in acute pancreatitis. Antioxidants. 2023;12:100.","journal-title":"Antioxidants."},{"key":"8906_CR69","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141\u201360.","journal-title":"Cancer Drug Resist"},{"key":"8906_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00627-5","volume":"19","author":"Y Li","year":"2021","unstructured":"Li Y, Wang Z, Ajani JA, Song S. Drug resistance and cancer stem cells. Cell Commun Signal. 2021;19:19.","journal-title":"Cell Commun Signal"},{"key":"8906_CR71","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","volume":"35","author":"M Nikolaou","year":"2018","unstructured":"Nikolaou M, Pavlopoulou A, Georgakilas AG, Kyrodimos E. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35:309\u201318.","journal-title":"Clin Exp Metastasis"},{"key":"8906_CR72","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science. 2022;377:1180\u201391.","journal-title":"Science."},{"key":"8906_CR73","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41588-024-01979-1","volume":"56","author":"W Guo","year":"2024","unstructured":"Guo W, Zhang X, Li L, Shao P, Liang C, Zhang H, et al. JAK\/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination. Nat Genet. 2024;56:2776\u201389.","journal-title":"Nat Genet"},{"key":"8906_CR74","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8(+) T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40:365\u201378.e6.","journal-title":"Cancer Cell"},{"key":"8906_CR75","doi-asserted-by":"publisher","first-page":"102857","DOI":"10.1016\/j.redox.2023.102857","volume":"66","author":"PZ Kong","year":"2023","unstructured":"Kong PZ, Yang MM, Wang Y, Yu KN, Wu LJ, Han W. Ferroptosis triggered by STAT1-IRF1-ACSL4 pathway was involved in radiation-induced intestinal injury. Redox Biol. 2023;66:102857.","journal-title":"Redox Biol"},{"key":"8906_CR76","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cell.2024.10.047","volume":"188","author":"YQ Wang","year":"2025","unstructured":"Wang YQ, Hu MZ, Cao J, Wang FX, Han JR, Wu TW, et al. ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization. Cell. 2025;188:412\u201329.","journal-title":"Cell."},{"key":"8906_CR77","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/0008-5472.CAN-23-2491","volume":"84","author":"YX Qiu","year":"2024","unstructured":"Qiu YX, Wang X, Sun Y, Jin T, Tang R, Zhou XY, et al. ACSL4-mediated membrane phospholipid remodeling induces integrin \u03b21 activation to facilitate triple-negative breast cancer metastasis. Cancer Res. 2024;84:1856\u201371.","journal-title":"Cancer Res"},{"key":"8906_CR78","doi-asserted-by":"publisher","first-page":"44849","DOI":"10.18632\/oncotarget.6438","volume":"6","author":"XY Wu","year":"2015","unstructured":"Wu XY, Deng FM, Li YR, Daniels G, Du XX, Ren QH, et al. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. Oncotarget. 2015;6:44849\u201363.","journal-title":"Oncotarget."},{"key":"8906_CR79","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247.","journal-title":"Nature."},{"key":"8906_CR80","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel D, Welsch M, Skouta R, Lee E, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.","journal-title":"Elife."},{"key":"8906_CR81","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.stem.2024.05.008","volume":"31","author":"JS Kirk","year":"2024","unstructured":"Kirk JS, Wang J, Long MR, Rosario S, Tracz A, Ji YB, et al. Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Cell Stem Cell. 2024;31:1203\u201321.e7.","journal-title":"Cell Stem Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08906-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08906-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:09:17Z","timestamp":1785521357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08906-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8906"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08906-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The Experimental Animal Welfare and Ethics Committee of the Southern University of Science and Technology approved all experimental animal procedures.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"665"}}